ストックスクリーナーアプリを入手
13.37
1.55%
-0.21
プレマーケット:
13.20
-0.17
-1.27%
Generate Biomedicines Inc (GENB) 最新ニュース
Generate Biomedicines Surges 9.69%: Breaking Resistance Levels in Biotech RallyIntraday Trade Ideas - newsline.com
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines, Inc. (GENB) Market Cap - Zacks Investment Research
GENB Price Today: Generate Biomedicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Why Is Generate Biomedicines, Inc. (GENB) Stock Down Today? - Meyka
Generate Biomedicines (GENB) Tumbles 7% as Selling Pressure Mounts – Key Support Levels in FocusSentiment Shift - newsline.com
Why Is Generate Biomedicines, Inc. (GENB) Stock Up Today? - Meyka
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains - Yahoo Finance
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x - simplywall.st
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Generate Biomedicines Inc. (GENB) Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue Development StageEarnings Analysis - newsline.com
Generate Biomedicines to Participate in Goldman Sachs Healthcare Conference on May 28, 2026 - geneonline.com
Generate Biomedicines (GENB) Stock News - Stock Titan
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
IPO Tracker 2026: Kardigan cozies up to public markets to support heart disease drugs - BioSpace
This AI biotech stock landed a $10.4 million Nvidia investment - MSN
Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer? - simplywall.st
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment - simplywall.st
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment - Yahoo Finance
A Deep Dive Into Nvidia’s Latest Portfolio Moves - Investing.com
Generate Biomedicines (GENB) News Flow - Moomoo
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - The Chronicle-Journal
Generate Biomedicines (GENB) Q1 2026 Miss: What Went WrongPretax Income Report - The Legal Advocate
Trades UpdateBuying More Generate BiomedicinesDeepDive - Moomoo
AI Protein Design Market 2026-2033 | Market Growth to FY (Q2) - openPR.com
Flagship entities disclose large GENB holdings, Flagship Pioneering holds 48.9% (GENB) - Stock Titan
Generate Biomedicines (NASDAQ: GENB) exec Michael Nally holds 5.2% stake - Stock Titan
Generate Biomedicines (GENB) Q1 2026 Disappoints — EPS $-1.06 Below $-0.51 ViewsGAAP Earnings Report - newsline.com
GENB : Generate Biomedicines, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
GENB: Generate Biomedicines, Inc.Brokerage Recommendations Chart - Zacks Investment Research
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Programmable Biology: Will GENB Generate Investor Interest? - RTTNews
Generate Biomedicines (GENB) price target increased by 10.47% to 24.22 - MSN
Generate Biomedicines, Inc. Stock 12‑Month Price Target Raised to $25.4, Implies 57% Upside - TradingView
Generate Biomedicines, Inc. (GENB) Ps Ratio (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Enterprise Value - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Free Cash Flow (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (Quarterly) - Zacks Investment Research
Dividend HistoryGenerate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Book Value - Zacks Investment Research
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):